Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (651-660 of 831) with videos related to

Pageof 84
Sort By:
Nature Communications|December 19, 2020
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtypeYonghe Wu, Michael Fletcher, Zuguang Gu, et al.
Journal for Immunotherapy of Cancer|August 31, 2025
HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometryLeon Bichmann, Ana Marcu, Daniel Johannes Kowalewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Neuro-Oncology|January 12, 2023
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selectionDavid Capper, Guido Reifenberger, Pim J French, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trialsMarijke Coomans, Linda Dirven, Neil K Aaronson, et al.
Nature|May 17, 2023
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastomaReza Naghavian, Wolfgang Faigle, Pietro Oldrati, et al.
The Lancet. Oncology|May 3, 2025
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of CancerFábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, et al.
Acta Neuropathologica|March 21, 2018
The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapyMarian Christoph Neidert, Daniel Johannes Kowalewski, Manuela Silginer, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
Pageof 84

Showing results (651-660 of 831) with videos related to

Sort By:
Pageof 84
Nature Communications|December 19, 2020
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtypeYonghe Wu, Michael Fletcher, Zuguang Gu, et al.
Journal for Immunotherapy of Cancer|August 31, 2025
HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometryLeon Bichmann, Ana Marcu, Daniel Johannes Kowalewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Neuro-Oncology|January 12, 2023
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selectionDavid Capper, Guido Reifenberger, Pim J French, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trialsMarijke Coomans, Linda Dirven, Neil K Aaronson, et al.
Nature|May 17, 2023
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastomaReza Naghavian, Wolfgang Faigle, Pietro Oldrati, et al.
The Lancet. Oncology|May 3, 2025
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of CancerFábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, et al.
Acta Neuropathologica|March 21, 2018
The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapyMarian Christoph Neidert, Daniel Johannes Kowalewski, Manuela Silginer, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
Pageof 84